You may have seen Pharmaceutical Benefit Managers (PBMs) in the news recently, but what are they? Essentially, they are ...

President Donald Trump stands with Centers for Medicare & Medicaid Services Administrator Mehmet Oz and Health and Human Services Secretary Robert F. Kennedy Jr. as he holds an executive order related ...

Novo Nordisk just announced price cuts for Ozempic and Wegovy, whose list prices as recently as last year were around $1,000 a month. Patients buying directly from the manufacturer will be able to pay ...

The House of Representatives just passed a resolution condemning the “horrors of socialism” by a 285 to 98 margin. All the no votes were cast by Democrats indicating that a majority of the members ...

Approximately 3.2 million Americans suffering from cancer, heart disease, and other serious or life-threatening diseases benefit from home infusion therapy. As the name suggests, home infusion therapy ...

Whatever political opposition existed around restricting drug prices through government intervention — and there was quite a lot not so long ago — seems to have largely disappeared. In other words, ...

"By capping physician pay, Medicare is making it difficult for many practices to keep their doors open," writes health expert Sally Pipes. "The new CMS fee schedule will only accelerate this grim ...

For decades, America’s drug-price debate has centered on a fundamental tension: How do policymakers encourage expensive research and development, while ensuring that companies keep final prices ...

Insurance in America is a strange business when the only people who reliably win are the middlemen. For years, the political right has rightly warned that government price controls on medicines would ...

Allison Schrager is a Bloomberg Opinion columnist covering economics. A senior fellow at the Manhattan Institute, she is author of “An Economist Walks Into a Brothel: And Other Unexpected Places to ...

Remember when Republican presidential candidate Donald Trump castigated “Comrade Kamala” Harris, then the Democratic nominee, for supporting price controls? It wasn’t that long ago — just last August.